Compare State Street SPDR S&P Biotech ETF (XBI) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs State Street Real Estate Select Sector SPDR ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while State Street Real Estate Select Sector SPDR ETF trades at $41.61 (market cap $7.61B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| XBI | XLRE | |
|---|---|---|
Market Cap | $10.11B | $7.61B |
Volume | 12,903,266 | 7,876,569 |
Sector | Broad Market / Factor | Sector/Thematic |
52-Week High | $169.55 | $46.01 |
52-Week Low | $104.99 | $40.01 |
Typical Hold Time | 38 Days | 75 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.61, up 2.56% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The ETF offers a low expense ratio of 0.08% and focuses on 30 U.S. large-cap real estate holdings, providing concentrated exposure to the domestic market. Recent news highlights comparisons with global real estate ETFs and discussions on value amid rising bond yields.
The outlook for XLRE is cautious due to bearish technicals and sensitivity to interest rate fluctuations, though its low cost and U.S. focus present a streamlined real estate investment option. Key risks include macroeconomic pressures from potential rate hikes and sector underperformance relative to digital infrastructure themes, requiring careful monitoring of Fed policy and real estate market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
